Application of euphorbia factor L2 to preparation of medicine for treating rheumatoid arthritis

A technology of euphorbia factor and arthritis, which is applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., and can solve the problems such as the absence of euphorbia factor L2

Active Publication Date: 2019-03-05
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no study on Euphorbia factor L2 as an antirheumatic drug in animal disease models or clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of euphorbia factor L2 to preparation of medicine for treating rheumatoid arthritis
  • Application of euphorbia factor L2 to preparation of medicine for treating rheumatoid arthritis
  • Application of euphorbia factor L2 to preparation of medicine for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Pharmacodynamic Study of Euphorbia Factor L2 in Treating Rheumatoid Arthritis

[0025] 1. Experimental method

[0026] Arthritis-susceptible K / BxN model mice were obtained by crossing K / B mice with NOD / Lt mice. The peripheral blood of K / BxN mice aged 6-8 weeks was collected and centrifuged at 4000rpm for 15min to prepare serum. Thirty-six 8-week-old male C57BL / 6N mice were randomly divided into three groups: normal control group, model group and euphorbia factor L2 treatment group. Serum-induced arthritis (SIA) model (Serum-induced arthritis, SIA) was established by intraperitoneal injection of 150 μl K / BxN mouse serum, and the day of injection was recorded as d 0 day. The intraperitoneal injection of euphorbia factor L2 (40 mg / kg) was started one day before modeling, and the administration was continued every day until the end of the experiment. The thickness of the hind paws and ankle joints of the mice was measured every day to evaluate the development ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses separation and preparation of a euphorbia factor L2 and a novel application of the euphorbia factor L2 to treatment of rheumatoid arthritis, and belongs to the field of traditional Chinese medicines. The euphorbia factor L2 is a diterpene ester compound extracted from semen euphorbiae lathyridis serving as a traditional Chinese medicinal material and displays good treatmenteffects on a serum metastasis induced inflammatory arthritis mouse model, and the euphorbia factor L2 has exact functions of resisting osteoarticular inflammatory diseases such as the rheumatoid arthritis and can be combined with auxiliary materials to prepare a medicine for resisting the inflammatory diseases such as the rheumatoid arthritis or combined with other medicines for treating the rheumatoid arthritis in application.

Description

technical field [0001] The invention relates to the application of euphorbia factor L2, an active component of the traditional Chinese medicine Stephania chinensis, in the preparation of medicines for treating rheumatoid arthritis, and belongs to the field of traditional Chinese medicines. Background technique [0002] Rheumatoid arthritis (RA) is a common chronic autoimmune disease characterized by synovitis. According to the data of the World Health Organization, the global incidence of RA is about 1%, which seriously endangers human health and reduces the quality of life. The main pathological changes of RA include synovitis and destruction of articular bone and cartilage, the latter being the direct cause of progressive joint ankylosis, deformity, dysfunction and even disability. At present, the treatment of RA is mainly to relieve pain, control inflammation, improve joint function and protect organs. The main measures include drug therapy, immune purification and surgi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P19/02A61P19/06A61P17/06A61P1/00A61P19/00
CPCA61K31/235A61K36/47
Inventor 罗玉斌成小兰刘毅王琦赵毅鲁晨阳陶伟伟易诗语
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap